Abhinav Goyal

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2446-54. 2005
  2. ncbi Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study
    Abhinav Goyal
    Duke Clinical Research Institute and Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Eur Heart J 27:1289-97. 2006
  3. doi Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
    James M Yau
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 102:546-51. 2008
  4. ncbi The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes
    Abhinav Goyal
    Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA
    Curr Cardiol Rep 6:300-7. 2004
  5. ncbi Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida
    Manesh R Patel
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Am Heart J 149:1009-19. 2005
  6. ncbi Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?
    Abhinav Goyal
    Duke Clinical Research Insitute, Durham, NC 27715, USA
    Am Heart J 150:650-1. 2005
  7. ncbi Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery
    Abhinav Goyal
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Thorac Surg 83:993-1001. 2007
  8. ncbi Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction
    Rafael Diaz
    Etudios Cardiologica Latin America, Rosario, Argentina
    JAMA 298:2399-405. 2007
  9. ncbi Stress test criteria used in the conservative arm of the FRISC-II trial underdetects surgical coronary artery disease when applied to patients in the VANQWISH trial
    Abhinav Goyal
    University of Pennsylvania School of Medicine, Department of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Coll Cardiol 39:1601-7. 2002
  10. ncbi Usefulness of the TIMI risk score in predicting both short- and long-term outcomes in the Veterans Affairs Non-Q-Wave Myocardial Infarction Strategies In-Hospital (VANQWISH) Trial
    Frederick F Samaha
    Cardiovascular Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Am J Cardiol 90:922-6. 2002

Detail Information

Publications12

  1. ncbi Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2446-54. 2005
    ..Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure...
  2. ncbi Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study
    Abhinav Goyal
    Duke Clinical Research Institute and Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Eur Heart J 27:1289-97. 2006
    ..We evaluated the prognostic significance of baseline glucose and the change in glucose in the first 24 h following AMI...
  3. doi Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
    James M Yau
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 102:546-51. 2008
    ..Further research is needed into the prevention and treatment of perioperative MI in patients undergoing CABG...
  4. ncbi The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes
    Abhinav Goyal
    Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA
    Curr Cardiol Rep 6:300-7. 2004
    ....
  5. ncbi Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida
    Manesh R Patel
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Am Heart J 149:1009-19. 2005
  6. ncbi Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?
    Abhinav Goyal
    Duke Clinical Research Insitute, Durham, NC 27715, USA
    Am Heart J 150:650-1. 2005
  7. ncbi Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery
    Abhinav Goyal
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Thorac Surg 83:993-1001. 2007
    ..We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes...
  8. ncbi Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction
    Rafael Diaz
    Etudios Cardiologica Latin America, Rosario, Argentina
    JAMA 298:2399-405. 2007
    ..While some smaller trials suggest benefit, in the CREATE-ECLA trial, GIK infusion had no effect on 30-day mortality in 20,201 patients...
  9. ncbi Stress test criteria used in the conservative arm of the FRISC-II trial underdetects surgical coronary artery disease when applied to patients in the VANQWISH trial
    Abhinav Goyal
    University of Pennsylvania School of Medicine, Department of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Coll Cardiol 39:1601-7. 2002
    ....
  10. ncbi Usefulness of the TIMI risk score in predicting both short- and long-term outcomes in the Veterans Affairs Non-Q-Wave Myocardial Infarction Strategies In-Hospital (VANQWISH) Trial
    Frederick F Samaha
    Cardiovascular Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Am J Cardiol 90:922-6. 2002
    ..76). No significant difference in outcomes between strategies was detected for a score > or =3. The TIMI risk score provides moderate incremental prognostic information in high-risk patients, during both short- and long-term follow-up...
  11. doi Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study
    Karen Chen
    The School of Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas 75235 9047, USA
    Diab Vasc Dis Res 5:96-101. 2008
    ..In conclusion, both MetS and DM are independently associated with an increased prevalence of atherosclerosis, with the highest observed prevalence in subjects with both DM and MetS...
  12. ncbi The burden of cardiovascular disease in the Indian subcontinent
    Abhinav Goyal
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
    Indian J Med Res 124:235-44. 2006
    ..Finally, we suggest measures to implement in policy, capacity building, and research to address the CVD epidemic in the Indian subcontinent...